EU approves Eisai's breast cancer drug Halaven

03/24/2011 |

European regulators approved Eisai's injectable drug Halaven to treat certain breast cancer patients who have received at least two chemotherapy regimens. The treatment is based on a sea sponge that is thought to inhibit growth of cancer cells.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC